About Us

About Us
Company Profile History Business Philosophy Company Honors

Science and Medicine

Science and Medicine
Science and Medicine R&D System R&D Team R&D Platform Pipe Layout Pharmacovigilance

Production and Quality

Production and Quality
Manufacturing facility Quality Management System

Global Operations

Global Operations
Commercialization Global Collaboration

News

News
Company News

Career Development

Career Development
Talent Philosophy Employee Development

Contact Us

Contact Us
Contact Us Adverse Event Reporting

EN

Menu

About Us
Company Profile History Business Philosophy Company Honors

Science and Medicine
Science and Medicine R&D System R&D Team R&D Platform Pipe Layout Pharmacovigilance

Production and Quality
Manufacturing facility Quality Management System

Global Operations
Commercialization Global Collaboration

News
Company News

Career Development
Talent Philosophy Employee Development

Contact Us
Contact Us Adverse Event Reporting

get in touch

Phone number

400-9963695

Email

PR@jeyoupharma.com

Address

Jimin Kexin (Shanghai) Pharmaceutical Industrial Park, Lane 535, Huanqiao Road, Pudong New Area, Shanghai, China
About Us
Company Profile History Business Philosophy Company Honors
Science and Medicine
Science and Medicine R&D System R&D Team R&D Platform Pipe Layout Pharmacovigilance
Production and Quality
Manufacturing facility Quality Management System
Global Operations
Commercialization Global Collaboration
News
Company News
Career Development
Talent Philosophy Employee Development
Contact Us
Contact Us Adverse Event Reporting

Science and Medicine

Jeyou Pharma specializes in the research, development, manufacturing, and commercialization of innovative medicines. Focusing on a “3+1” indication matrix—including oncology, nephrology, pain, and autoimmune diseases—the company is committed to providing patients worldwide with medicines that offer unique clinical value and address unmet medical needs. Jeyou Pharma has established an end-to-end R&D system covering project selection and initiation, innovative drug discovery, preclinical pharmacology and toxicology studies, clinical trials, regulatory filing and market launch, as well as comprehensive project management, thereby building a one-stop R&D capability spanning from drug discovery to regulatory submission and market launch.

Focused on the research and commercialization of innovative drugs; providing medications with unique clinical value

Drug Discovery
Clinical Development
Drug Registration
Pharmacovigilance
Renowned universities
Top-tier hospitals
International R&D Organization

Jeyou Pharma integrates molecular design, clinical pathway design, CMC processes, and regulatory strategies into a unified project management framework, ensuring a seamless transition from the laboratory to clinical trials. The company has established a data-driven, full-lifecycle management system to enable real-time monitoring of the R&D process and optimize resource allocation. Additionally, Jeyou Pharma has forged partnerships with leading global research institutions and multinational pharmaceutical companies to enhance its technological capabilities and has assembled a team of external expert advisors to provide scientific support for major decision-making.

R&D Team

Jeyou Pharma’s core team of scientists each has over 15 years of experience in drug discovery and development, including experience at large multinational pharmaceutical companies. They have led or participated in the development of numerous new drugs that are now on the market or in clinical trials, and have achieved significant success in the development of innovative drugs.

R&D staff
Ph.D.
Percentage of Master's Degree Holders
Years of R&D

5 High-Performance TechnologyPlatforms Unique to AI-Driven Companies

Through iterative development using an AI platform, Jiyu Pharmaceutical has established five R&D platforms that feature exceptionally high competitive barriers and efficiency.

JY

JY

RDPL-PROTAC: A PROTAC platform for rapid molecular design based on proprietary ligands and computational methods

RDPL-PROTAC: A PROTAC platform for rapid molecular design based on proprietary ligands and computational methods

Project Applications: JMKX002992，JMN-2505，JMN-2506

  • Using platform technology, PROTAC molecules with high biological activity and favorable pharmacokinetics can be efficiently designed for degradation targets.

  • Maturation and storage of the proprietary E3 ligand

  • AIDD's Computationally Enabled Multi-Dimensional Capabilities for Efficient Advancement

JY

JY

MAAD-AI Design Integrated Algorithm-Driven AI-Powered Drug Discovery Platform

MAAD-AI Design Integrated Algorithm-Driven AI-Powered Drug Discovery Platform

Project Applications: ~30 targets and projects

  • In-house development combined with external partnerships, with comprehensive software and hardware deployment of the latest algorithms and ample GPU computing power

  • Over 20 software tools, including industry-leading AI capabilities such as structure prediction, dynamics simulation, molecular generation, and FEP calculations

  • Empowering molecular design, accelerating the FF project, and launching the FIC project

JY

JY

CABA-Discovery Cytokine-Activated Bispecific Antibody Discovery Platform

CABA-Discovery Cytokine-Activated Bispecific Antibody Discovery Platform

Project Applications: 2401 bispecific antibody, 2403, and other innovative trispecific antibody projects

  • Analysis of millions of antibody sequences

  • Increased the throughput of antibody sequence screening by a factor of thousands

  • Identify novel epitopes that cannot be identified using many traditional methods

JY

JY

YDBS-Screen Yeast-Based Light Chain Dual-Antibody Screening Platform

YDBS-Screen Yeast-Based Light Chain Dual-Antibody Screening Platform

Project Applications: 2005, 2202, and other light-chain-targeted bispecific antibody projects

  • A dual-antibody screening and optimization platform for yeast surfaces

  • An Innovative Yeast Display Platform Based on IgG Formats

  • Scaling up antibody sequence discovery to millions of sequences per run

JY

JY

Pepfold–DRP A platform for the precise folding of polycyclic peptides via disulfide bonds

Pepfold–DRP A platform for the precise folding of polycyclic peptides via disulfide bonds

Project Application: JMKX2301, trans-brain peptide conjugate

  • A large-scale library of 109-mer peptides and a unique library of polycyclic peptides containing multiple disulfide bonds

  • Significantly improve the success rate of producing correctly folded multipeptide chains

RDPL-PROTAC: A PROTAC platform for rapid molecular design based on proprietary ligands and computational methods

Project Applications: JMKX002992，JMN-2505，JMN-2506

  • Using platform technology, PROTAC molecules with high biological activity and favorable pharmacokinetics can be efficiently designed for degradation targets.

  • Maturation and storage of the proprietary E3 ligand

  • AIDD's Computationally Enabled Multi-Dimensional Capabilities for Efficient Advancement

MAAD-AI Design: An Integrated Algorithm-Driven AI-Enabled Drug Discovery Platform

Project Applications: ~30 targets and projects

  • In-house development combined with external partnerships, with comprehensive software and hardware deployment of the latest algorithms and ample GPU computing power

  • Over 20 software tools, including industry-leading AI capabilities such as structure prediction, dynamics simulation, molecular generation, and FEP calculations

  • Empowering molecular design, accelerating the FF project, and launching the FIC project

CABA-Discovery Cytokine-Activated Bispecific Antibody Discovery Platform

Project Applications: 2401 bispecific antibody, 2403, and other innovative trispecific antibody projects

  • Analysis of millions of antibody sequences

  • Increased the throughput of antibody sequence screening by a factor of thousands

  • Identify novel epitopes that cannot be identified using many traditional methods

YDBS-Screen Yeast-Based Light Chain Dual-Antibody Screening Platform

Project Applications: 2005, 2202, and other light-chain-targeted bispecific antibody projects

  • A dual-antibody screening and optimization platform on yeast surfaces
  • An Innovative Yeast Display Platform Based on IgG Formats
  • Scaling up antibody sequence discovery to millions of sequences per run
Pepfold–DRP A platform for the precise folding of polycyclic peptides via disulfide bonds

Project Application: JMKX2301, trans-brain peptide conjugate

  • A large-scale library of 109-mer peptides and a unique library of polycyclic peptides containing multiple disulfide bonds
  • Significantly improve the success rate of producing correctly folded multipeptide chains

Key R&DPipelines and Projects

Over 40 projects currently in development:including over 30 small-molecule projects and over 10 large-molecule projects, with 9 in Phase II clinical trials and 10 in Phase I clinical trials

Kidney disease
Tumor
Pain
Autoimmunity and Other Conditions
Featured Products Mechanism/Target Indications PCC IND PH1 PH2 PH3 Partner

JMKX003142

 V2R ADPKD
Renal edema

JMKX003142-IV

 Cardiac edema

JMKX003002

 NHE3 Hyperphosphatemia (in hemodialysis patients)

JMB-2201

 -

JMKX001899

 KRAS-G12C 2L NSCLC

Key Clinical Trials

JMKX000197

 STING Malignant pleural effusion

JMB-2301

 -

JMKX000189

 S1P1 CIPN
UC

JYB1904

 lgE Asthma
Chronic idiopathic urticaria
Chronic rhinitis

JMKX003948

 Hif2a wAMD

JMKX002992

 AR Tumor

Pharmacovigilance

Jeyou Pharmaceuticals has established a comprehensive pharmacovigilance system to manage the safety of its products throughout their entire lifecycle. Team members possess strong medical backgrounds and extensive experience in the pharmacovigilance industry, ensuring that all pharmacovigilance activities fully comply with the requirements of relevant regulatory authorities. Based on ICH technical guidelines, the Pharmacovigilance Department has developed sustainable improvement protocols centered on safety information monitoring, evaluation, and risk management. Through continuous oversight of the implementation of the quality policy, the department maintains and enhances the compliant operation of the pharmacovigilance system. By fully fulfilling its responsibilities for safety information monitoring, identification, evaluation, and risk management, the Pharmacovigilance Department continuously refines the safety profiles of the company’s products while minimizing product safety risks to the greatest extent possible. This ensures a favorable benefit-risk balance to protect and promote public health.

 

If a patient experiences a suspected adverse event, please consult a healthcare professional. To report an adverse event to us, please contact jyadr@jeyoupharma.com.